Please ensure Javascript is enabled for purposes of website accessibility

Could Novavax Win U.S. Authorization for Its COVID Vaccine Sooner Than Expected?

By Keith Speights and Brian Orelli, PhD - Feb 10, 2021 at 6:04AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Novavax's CEO hopes so.

Novavax (NVAX -3.78%) recently reported very good results from a late-stage study conducted in the United Kingdom of its COVID-19 vaccine candidate. The company's CEO wants the U.S. Food and Drug Administration (FDA) to consider emergency use authorization for the vaccine based on this U.K. data rather than waiting a few months for results from a U.S. late-stage study. In this Motley Fool Live video recorded on Feb. 3, 2021, contributors Keith Speights and Brian Orelli discuss whether or not Novavax could win U.S. authorization for its COVID vaccine sooner than expected.

Keith Speights: Hey, speaking of Novavax, the company's CEO, Stanley Erck, said something interesting late last week. He stated that he thinks the FDA should allow the use of that U.K. data for its U.S. emergency use authorization filing. Eric said that Novavax is talking with FDA about this possibility. What do you think the odds are that the FDA are going to go along with this idea?

Brian Orelli: I think if we didn't have any other vaccines, I think that that would be a lot more likely than now we have two vaccines and they seem to be churning along manufacturing. I think it's less likely now with them being the third vaccine than it would be if they were the only vaccine.

I think if they were the only vaccine, I think that the FDA would be more likely to go along with that. But given that it's only going to speed up the launch of Novavax's vaccine by a couple of months, and we already have vaccine coming out, I'm not sure that it really matters that much.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
$51.40 (-3.78%) $-2.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.